ZD1839, a novel, oral epidermal growth factor receptor-tyrosine kinase inhibitor, as salvage treatment in patients with advanced non-small cell lung cancer. Experience from a single center participating in a compassionate use program (Q44462012)

From Wikidata

Jump to navigation Jump to search

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

scientific article

Language	Label	Description	Also known as
English	ZD1839, a novel, oral epidermal growth factor receptor-tyrosine kinase inhibitor, as salvage treatment in patients with advanced non-small cell lung cancer. Experience from a single center participating in a compassionate use program	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

ZD1839, a novel, oral epidermal growth factor receptor-tyrosine kinase inhibitor, as salvage treatment in patients with advanced non-small cell lung cancer. Experience from a single center participating in a compassionate use program (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

expanded access

1 reference

based on heuristic

inferred from title

author name string

A G Pallis

1

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

D Mavroudis

2

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

N Androulakis

3

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

J Souglakos

4

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

C Kouroussis

5

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

V Bozionelou

6

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

I G Vlachonikolis

7

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

V Georgoulias

8

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

publication date

1 June 2003

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

40

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

301-307

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Epidermal growth factor receptor family in lung cancer and premalignancy

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900079-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Kinase inhibitors in cancer therapy: a look ahead

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900079-5

7 January 2021

based on heuristic

inferred from DOI database lookup

A comparison of epidermal growth factor receptor levels and other prognostic parameters in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900079-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900079-5

7 January 2021

based on heuristic

inferred from DOI database lookup

The role of amphiregulin in breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900079-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Epidermal growth factor-related peptides and their receptors in human malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900079-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900079-5

7 January 2021

based on heuristic

inferred from DOI database lookup

ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900079-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900079-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900079-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900079-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Assessment of quality-of-life outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900079-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Quality of life assessment in individuals with lung cancer: testing the Lung Cancer Symptom Scale (LCSS).

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900079-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Normative data and trends in quality of life from the Lung Cancer Symptom Scale (LCSS).

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900079-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900079-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2803%2900079-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0169-5002(03)00079-5

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44462012&oldid=2024801775"